Good News from Aurinia Pharmaceuticals for Lupus Nephritis
September 25, 2018 Congratulations to Aurinia Pharmaceuticals for completing patient enrollment in the AURORA Phase 3 clinical trial ahead of schedule. The company reported in a press release issued today that due to high patient demand, the target number of patients was surpassed with 358 lupus nephritis (LN) patients enrolled in sites across 27 countries. […]
Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study
Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at the World Congress of Nephrology reported that results of the Phase III REGENCY trial found that among people with active lupus nephritis, Gazyva® (obinutuzumab) plus standard therapy demonstrated statistically significant and clinically meaningful improvement in the […]
Patients with Lupus Nephritis-Related Kidney Disease Are Living Longer
March 28, 2019 A new study published this March in Arthritis & Rheumatology found that deaths among patients with end-stage renal disease (ESRD) due to lupus nephritis (LN) fell significantly — by 32% —over the past two decades. The study took into account deaths from all causes, including deaths from cardiovascular disease (CVD) and infection. […]
Aurinia Moves Voclosporin Closer to FDA Approval for Lupus Nephritis
March 16, 2020 The Lupus Research Alliance is pleased to share an announcement from Aurinia Pharmaceuticals that moves its potential treatment for lupus nephritis, voclosporin, one step closer to approval by the U.S. Food and Drug Administration (FDA). The Company announced in a press release March 16 that it has started a Rolling Submission of […]
Better Survival Rates from Severe Lupus Nephritis
September 20, 2018 Significantly more people are surviving end-stage renal (kidney) disease caused by lupus nephritis according to a long-term analysis published in Arthritis & Rheumatology. The analysis of the national registry of 20,974 patients with end-stage renal disease (ESRD) during the years 1995 through 2014 found that mortality rates significantly declined. In addition, among […]
LRA Announces Inaugural Awards Promoting Diversity in Lupus Research
NEW YORK, NY, June 9, 2022. The Lupus Research Alliance (LRA), the world’s leading private funder of lupus research, today announced inaugural recipients of Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research. The Diversity in Lupus Research Award funding mechanisms aim to address underrepresentation of minorities in the scientific research profession. Lupus […]
Lupus Research Alliance Announces 10 Recipients of New Award in Partnership with Bristol Myers Squibb
NEW YORK, NY. July 14, 2020 — The Lupus Research Alliance (LRA) is pleased to announce the recipients of the inaugural LRA-BMS Accelerator Award*, a collaborative project with sponsoring partner Bristol Myers Squibb. The Award provides a collective total of $3,000,000 to support ten cutting-edge lupus research projects over two years that focus on […]
Breadth of Clinical Research Presented at the 2019 ACR/ARP Annual Meeting Brings Hope for New Lupus Treatments
November 14, 2019 The Lupus Research Alliance staff was on the ground at the 2019 ACR/ARP Annual Meeting and highly encouraged by the positive results reported for several potential new treatments that may help people with lupus. “The foundational work the Lupus Research Alliance and others have supported is beginning to bear fruit with potential […]
2018 Distinguished Innovator Awardees Named by Lupus Research Alliance
NEW YORK, NY. December 20. The Lupus Research Alliance is proud to announce the 2018 recipients of the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity: Nir Hacohen, PhD (right) and Vijay Kuchroo, DVM, PhD (left). Dr. Hacohen is seeking better ways to treat lupus kidney disease, the major cause of illness and […]
Lupus Research Alliance Announces Inaugural Recipients of Translational Bridge Award
The Lupus Research Alliance (LRA) is excited to announce the first-ever recipients of the Translational Bridge Award (TBA), established this year to accelerate the translation of groundbreaking research into potential treatments and diagnostics for lupus. The award aims to propel high-potential projects from LRA-funded foundational discoveries with strong commercialization potential or an opportunity for clinical […]
Promising New Lupus Treatments Highlighted ACR Annual Meeting
Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm […]
New Treatment Approaches Supported by LRA Were Highlighted at LUPUS 2019
April 11, 2019 The bacteria that cause urinary tract infections may trigger lupus flares, a former Alzheimer’s disease therapy has shown promising results in research models—these are just some of the findings presented by Lupus Research Alliance-funded scientists at the 13th International Congress on Systematic Lupus Erythematosus (LUPUS 2019), held in San Francisco. Here are […]